A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT03311334. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT03311334
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Enrollment
- 47 participants
Conditions and interventions
Conditions
Interventions
- DSP-7888 Dosing Emulsion Drug
- Nivolumab Drug
- Pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 13, 2017
- Primary completion
- Oct 18, 2022
- Completion
- Nov 28, 2022
- Last update posted
- Apr 17, 2024
2017 – 2022
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC - HOPE | Tucson | Arizona | 85711 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| UC San Francisco Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94143 | — |
| Rocky Mountain Cancer Centers | Aurora | Colorado | 80012 | — |
| AdventHealth Cancer Institute | Orlando | Florida | 32804 | — |
| Decatur Memorial Hospital | Decatur | Illinois | 62526 | — |
| Horizon Oncology Research | Lafayette | Indiana | 47905 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40241 | — |
| St Vincent Frontier Cancer Center | Billings | Montana | 59102 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| UC Health, LLC | Cincinnati | Ohio | 45229 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| West Cancer Clinic | Germantown | Tennessee | 38138 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75251 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| Summit Cancer Centers | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03311334, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 17, 2024 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03311334 live on ClinicalTrials.gov.